Cyclical alendronate treatment in postmenopausal women with osteoporosis.
Köşüş
A
A
Department of Obstetrics and Gynecology, Selcuk University, Meram Faculty of Medicine, Konya, Turkey. aydinkosus@ttnet.net.tr
Capar
M
M
Köşüş
N
N
D019386:Alendronate / Q000008:administration & dosage* / Q000191:economics; D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000191:economics; D002118:Calcium / Q000652:urine; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000008:administration & dosage* / Q000191:economics; D005260:Female; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010758:Phosphorus / Q000652:urine
D000596:Amino Acids; D050071:Bone Density Conservation Agents; D015675:Osteocalcin; D010758:Phosphorus; C036020:deoxypyridinoline; D000469:Alkaline Phosphatase; D012968:Etidronic Acid; D002118:Calcium; D019386:Alendronate